🔗 Share this article

As the US continues making sweeping adjustments to its vaccination recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who rose to prominence by expressing skepticism about coronavirus shots throughout the global health crisis and has concentrated on possible deaths following Covid vaccination in her recent tenure at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Health officials planned to unveil sweeping changes to the pediatric immunization program recently, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would put the US at odds with many the global community with insufficient data for benefit. The announcement has been postponed until the coming year.

In place of the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to head the office this year.

A Shift at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood shot schedules in the US to become more in line with Denmark's approach, a nation with nationalized medicine and a population roughly the size of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – traditionally the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Expertise

Dr. Høeg has little discernible experience in drug development, oversight or administrative roles, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in running a sizeable institution. She is not an expert in drug approvals.”

Former directors of the center would “grasp laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who led CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Everybody just focuses on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars division, non-prescription drug unit and other areas, and all of those must be supervised,” Woodcock said. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the position, which oversees in excess of 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” the former official concluded.

Official Statement and Disputed Policies

Regarding questions about Høeg’s qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries are based on flawed assumptions”.

“Her experience matches the duties of her job,” the spokesperson explained, noting the months Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a controversial one-day therapy clearance system that reportedly troubled her preceding directors. “How are these drugs being chosen for this fast-track system? Who makes the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the agency right now.”

Broadly speaking, he said, “the FDA looks to be trending towards laxer rules of pharmaceuticals, except for immunizations.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a more established, if concerning, past, Howard said. She released a research paper using unconfirmed crowd-sourced reports to assess the incidence of heart inflammation after Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are more dangerous than they are.

Among her “desired changes” for the incoming federal leadership encompassed changing guidelines for novel immunizations and halting “optional” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has according to sources proposed excluding adolescent males from obtaining COVID-19 vaccines.

“She is an complete ideologue who begins with her preconceived notions and reverse-engineers to retrofit the evidence in a very disingenuous, untruthful manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with other contrarians, {like|